38,900 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Allianz Asset Management GmbH

Key Points

• Allianz Asset Management GmbH acquired 38,900 shares of Amneal Pharmaceuticals, valued at approximately $326,000, indicating growing institutional interest in the company.
• Analysts have a consensus rating of "Buy" for Amneal Pharmaceuticals, with projections for a target price of $11.60 per share.
• Amneal Pharmaceuticals reported $0.19 earnings per share for the last quarter, surpassing analysts' expectations, though its revenue fell short of forecasts.

Allianz Asset Management GmbH bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 38,900 shares of the company's stock, valued at approximately $326,000.

Other large investors have also recently bought and sold shares of the company. Janney Montgomery Scott LLC lifted its holdings in Amneal Pharmaceuticals by 26.9% in the first quarter. Janney Montgomery Scott LLC now owns 19,350 shares of the company's stock worth $162,000 after acquiring an additional 4,100 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Amneal Pharmaceuticals by 53.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 60,567 shares of the company's stock worth $508,000 after acquiring an additional 21,079 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Amneal Pharmaceuticals by 45.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock worth $2,522,000 after acquiring an additional 99,866 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Amneal Pharmaceuticals by 10.3% in the fourth quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock worth $1,043,000 after acquiring an additional 12,282 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Amneal Pharmaceuticals by 209.2% in the fourth quarter. BNP Paribas Financial Markets now owns 168,194 shares of the company's stock worth $1,332,000 after acquiring an additional 113,796 shares during the last quarter. Institutional investors own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on AMRX shares. The Goldman Sachs Group started coverage on shares of Amneal Pharmaceuticals in a report on Friday, June 6th. They issued a "buy" rating and a $12.00 target price on the stock. Wall Street Zen cut shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $11.60.

Amneal Pharmaceuticals Trading Up 0.1%

AMRX opened at $7.83 on Monday. The business's 50 day moving average is $7.94 and its 200-day moving average is $7.96. The stock has a market cap of $2.45 billion, a PE ratio of -195.70 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.50 and a twelve month high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.05. The company had revenue of $695.42 million for the quarter, compared to analysts' expectations of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 188.26% and a negative net margin of 0.46%. As a group, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.